143 related articles for article (PubMed ID: 24778280)
1. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Liakou CI; Kamat A; Tang DN; Chen H; Sun J; Troncoso P; Logothetis C; Sharma P
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14987-92. PubMed ID: 18818309
[TBL] [Abstract][Full Text] [Related]
3. ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses.
Lownik JC; Luker AJ; Damle SR; Cooley LF; El Sayed R; Hutloff A; Pitzalis C; Martin RK; El Shikh MEM; Conrad DH
J Immunol; 2017 Oct; 199(7):2305-2315. PubMed ID: 28814605
[TBL] [Abstract][Full Text] [Related]
4. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
5. Deep Flow Cytometry Unveils Distinct Immune Cell Subsets in Inducible T Cell Co-Stimulator Ligand (ICOSL)- and ICOS-Knockout Mice during Experimental Autoimmune Encephalomyelitis.
Raineri D; Abreu H; Vilardo B; Kustrimovic N; Venegoni C; Cappellano G; Chiocchetti A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473756
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
[TBL] [Abstract][Full Text] [Related]
7. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Chen H; Liakou CI; Kamat A; Pettaway C; Ward JF; Tang DN; Sun J; Jungbluth AA; Troncoso P; Logothetis C; Sharma P
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2729-34. PubMed ID: 19202079
[TBL] [Abstract][Full Text] [Related]
8. ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
Sharma N; Fan X; Atolagbe OT; Ge Z; Dao KN; Sharma P; Allison JP
J Exp Med; 2024 Apr; 221(4):. PubMed ID: 38517331
[TBL] [Abstract][Full Text] [Related]
9. Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4
Zaidi N; Quezada SA; Kuroiwa JMY; Zhang L; Jaffee EM; Steinman RM; Wang B
Ann N Y Acad Sci; 2019 Jun; 1445(1):62-73. PubMed ID: 30945313
[TBL] [Abstract][Full Text] [Related]
10. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas F; Furness AJS; Litchfield K; Joshi K; Rosenthal R; Ghorani E; Solomon I; Lesko MH; Ruef N; Roddie C; Henry JY; Spain L; Ben Aissa A; Georgiou A; Wong YNS; Smith M; Strauss D; Hayes A; Nicol D; O'Brien T; Mårtensson L; Ljungars A; Teige I; Frendéus B; ; ; ; Pule M; Marafioti T; Gore M; Larkin J; Turajlic S; Swanton C; Peggs KS; Quezada SA
Cancer Cell; 2018 Apr; 33(4):649-663.e4. PubMed ID: 29576375
[TBL] [Abstract][Full Text] [Related]
11. Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency.
Abolhassani H; El-Sherbiny YM; Arumugakani G; Carter C; Richards S; Lawless D; Wood P; Buckland M; Heydarzadeh M; Aghamohammadi A; Hambleton S; Hammarström L; Burns SO; Doffinger R; Savic S
J Clin Immunol; 2020 Feb; 40(2):277-288. PubMed ID: 31858365
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
13. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P; Philips D; Kelderman S; Hageman L; Ottensmeier C; Joseph-Pietras D; Welters MJ; van der Burg S; Kapiteijn E; Michielin O; Romano E; Linnemann C; Speiser D; Blank C; Haanen JB; Schumacher TN
Sci Transl Med; 2014 Sep; 6(254):254ra128. PubMed ID: 25232180
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4: a moving target in immunotherapy.
Rowshanravan B; Halliday N; Sansom DM
Blood; 2018 Jan; 131(1):58-67. PubMed ID: 29118008
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Yap TA; Gainor JF; Callahan MK; Falchook GS; Pachynski RK; LoRusso P; Kummar S; Gibney GT; Burris HA; Tykodi SS; Rahma OE; Seiwert TY; Papadopoulos KP; Blum Murphy M; Park H; Hanson A; Hashambhoy-Ramsay Y; McGrath L; Hooper E; Xiao X; Cohen H; Fan M; Felitsky D; Hart C; McComb R; Brown K; Sepahi A; Jimenez J; Zhang W; Baeck J; Laken H; Murray R; Trehu E; Harvey CJ
Clin Cancer Res; 2022 Sep; 28(17):3695-3708. PubMed ID: 35511938
[TBL] [Abstract][Full Text] [Related]
16. Microbiota-dependent activation of CD4
Lo BC; Kryczek I; Yu J; Vatan L; Caruso R; Matsumoto M; Sato Y; Shaw MH; Inohara N; Xie Y; Lei YL; Zou W; Núñez G
Science; 2024 Jan; 383(6678):62-70. PubMed ID: 38175892
[TBL] [Abstract][Full Text] [Related]
17. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction.
Abdel-Rahman SA; Santini BL; Calvo-Barreiro L; Zacharias M; Gabr M
Bioorg Med Chem Lett; 2024 Feb; 99():129599. PubMed ID: 38185345
[TBL] [Abstract][Full Text] [Related]
18. BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.
Tseng HY; Alavi S; Gallagher S; McGuire HM; Hersey P; Al Emran A; Tiffen J
Pigment Cell Melanoma Res; 2024 May; ():. PubMed ID: 38725219
[TBL] [Abstract][Full Text] [Related]
19. ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control.
Blair T; Baird J; Bambina S; Kramer G; Gostissa M; Harvey CJ; Gough MJ; Crittenden MR
Sci Rep; 2022 Sep; 12(1):14954. PubMed ID: 36056093
[TBL] [Abstract][Full Text] [Related]
20. Transplantation elicits a clonally diverse CD8
Cohen GS; Kallarakal MA; Jayaraman S; Ibukun FI; Tong KP; Orzolek LD; Larman HB; Krummey SM
Cell Rep; 2023 Aug; 42(8):112993. PubMed ID: 37590141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
